Abstract: The present invention is directed to a method for combining assessment of different factors of dyssynchrony into a comprehensive, non-invasive toolbox for treating patients with a CRT therapy device. The toolbox provides high spatial resolution, enabling assessment of regional function, as well as enabling derivation of global metrics to improve patient response and selection for CRT therapy. The method allows for quantitative assessment and estimation of mechanical contraction patterns, tissue viability, and venous anatomy from CT scans combined with electrical activation patterns from Body Surface Potential Mapping (BSPM). This multi-modal method is therefore capable of integrating electrical, mechanical, and structural information about cardiac structure and function in order to guide lead placement of CRT therapy devices. The method generates regional electro-mechanical properties overlaid with cardiac venous distribution and scar tissue.

Abstract: An embodiment in accordance with the present invention provides a method for non-invasively determining the functional severity of coronary artery stenosis. The method includes gathering patient-specific data related to concentration of a contrast agent within a coronary artery of a patient using a coronary computed tomography angiography scan (CCTA). The patient-specific data is used to calculate a patient-specific transluminal attenuation gradient for the coronary artery of the patient. The patient specific transluminal attenuation gradient is used to determine an estimate of a coronary flow velocity, pressure gradient, loss coefficient, coronary flow reserve, and/or fractional flow reserve for the patient. Coronary flow velocity, pressure gradient, loss coefficient, coronary flow reserve, and fractional flow reserve can then be used to estimate the functional severity of coronary artery stenosis.

Abstract: The present invention is directed to a method for combining assessment of different factors of dyssynchrony into a comprehensive, non-invasive toolbox for treating patients with a CRT therapy device. The toolbox provides high spatial resolution, enabling assessment of regional function, as well as enabling derivation of global metrics to improve patient response and selection for CRT therapy. The method allows for quantitative assessment and estimation of mechanical contraction patterns, tissue viability, and venous anatomy from CT scans combined with electrical activation patterns from Body Surface Potential Mapping (BSPM). This multi-modal method is therefore capable of integrating electrical, mechanical, and structural information about cardiac structure and function in order to guide lead placement of CRT therapy devices. The method generates regional electro-mechanical properties overlaid with cardiac venous distribution and scar tissue.

Abstract: An embodiment in accordance with the present invention provides a method for non-invasively determining the functional severity of coronary artery stenosis. The method includes gathering patient-specific data related to concentration of a contrast agent within a coronary artery of a patient using a coronary computed tomography angiography scan (CCTA). The patient-specific data is used to calculate a patient-specific transluminal attenuation gradient for the coronary artery of the patient. The patient specific transluminal attenuation gradient is used to determine an estimate of a coronary flow velocity, pressure gradient, loss coefficient, coronary flow reserve, and/or fractional flow reserve for the patient. Coronary flow velocity, pressure gradient, loss coefficient, coronary flow reserve, and fractional flow reserve can then be used to estimate the functional severity of coronary artery stenosis.

Abstract: An embodiment in accordance with the present invention provides a method for non-invasively determining the functional severity of arterial stenosis in a selected portion of an arterial network. The method includes gathering patient-specific data related to concentration of a contrast agent within an arterial network using a coronary computed tomography angiography scan (CCTA). The data can be gathered under rest or stress conditions. Estimation of a loss coefficient (K) can be used to eliminate the need for data gathered under stress. The data is used to calculate a transluminal attenuation gradient (TAG). The data may be corrected for imaging artifacts at any stage of the analysis. TAFE is used to determine an estimate of flow velocity. Once velocity is determined, pressure gradient, coronary flow reserve, and/or fractional flow reserve can be determined through a variety of methods. These estimates can be used to estimate functional severity of stenosis.

Abstract: A shielded component or network for an active medical device (AMD) implantable lead includes an implantable lead having a length extending from a proximal end to a distal end, all external of an AMD housing, a passive component or network disposed somewhere along the length of the implantable lead, the passive component or network including at least one inductive component having a first inductive value, and an electromagnetic shield substantially surrounding the inductive component or the passive network. The first inductive value of the inductive component is adjusted to account for a shift in its inductance to a second inductive value when shielded.

Abstract: An energy management system facilitates the transfer of high frequency energy coupled into an implanted lead at a selected RF frequency or frequency band, to an energy dissipating surface. This is accomplished by conductively coupling the implanted lead to the energy dissipating surface through an energy diversion circuit including one or more passive electronic network components whose impedance characteristics are at least partially tuned to the implanted lead's impedance characteristics.

Abstract: A shielded component or network for an active medical device (AMD) implantable lead includes (1) an implantable lead having a length extending from a proximal end to a distal end, all external of an AMD housing, (2) a passive component or network disposed somewhere along the length of the implantable lead, the passive component or network including at least one inductive component having a first inductive value, and (3) an electromagnetic shield substantially surrounding the inductive component or the passive network. The first inductive value of the inductive component is adjusted to a account for a shift in its inductance to a second inductive value when shielded.

Abstract: A medical lead system includes at least one bandstop filter for attenuating current flow through the lead across a range of frequencies. The bandstop filter has an overall circuit Q wherein the resultant 3 dB bandwidth is at least 10 kHz. The values of capacitance and inductance of the bandstop filter are selected such that the bandstop filter is resonant at a selected center frequency or range of frequencies. Preferably, the bandstop filter has an overall circuit Q wherein the resultant 10 dB bandwidth is at least 10 kHz. Such bandstop filters are backwards compatible with known implantable deployment systems and extraction systems.

Abstract: An energy management system that facilitates the transfer of high frequency energy induced on an implanted lead or a leadwire includes an energy dissipating surface associated with the implanted lead or the leadwire and at least one non-linear circuit element switch for diverting energy in the implanted lead or the leadwire to the energy dissipating surface. In alternate configurations, the switch may be disposed so that it electrically opens the implanted lead or the leadwire when diverting energy to the energy dissipating surface. The non-linear circuit element switch is typically a PIN diode.

Abstract: A shielded component or network for an active medical device (AMD) implantable lead includes an implantable lead having a length extending from a proximal end to a distal end, all external of an AMD housing, a passive component or network disposed somewhere along the length of the implantable lead, the passive component or network including at least one inductive component having a first inductive value, and an electromagnetic shield substantially surrounding the inductive component or the passive network. The first inductive value of the inductive component is adjusted to account for a shift in its inductance to a second inductive value when shielded.

Abstract: A lead extending exteriorly from an active implantable medical device (AIMD) is at least partially ensheathed within an electromagnetic interference (EMI) shield. The AIMD has a conductive equipotential surface to which the EMI shield may be conductively coupled. An impeding circuit may be provided for raising the high frequency impedance of the lead. An energy diversion circuit may also be provided for conductively coupling the lead to the EMI shield.

Abstract: An energy management system that facilitates the transfer of high frequency energy induced on an implanted lead or a leadwire includes an energy dissipating surface associated with the implanted lead or the leadwire, a diversion or diverter circuit associated with the energy dissipating surface, and at least one non-linear circuit element switch for diverting energy in the implanted lead or the leadwire through the diversion circuit to the energy dissipating surface. In alternate configurations, the switch may be disposed between the implanted lead or the leadwire and the diversion circuit, or disposed so that it electrically opens the implanted lead or the leadwire when diverting energy through the diversion circuit to the energy dissipating surface. The non-linear circuit element switch is typically a PIN diode. The diversion circuit may be either a high pass filter or a low pass filter.

Abstract: An embodiment in accordance with the present invention provides a method for non-invasively determining the functional severity of arterial stenosis in a selected portion of an arterial network. The method includes gathering patient-specific data related to concentration of a contrast agent within an arterial network using a coronary computed tomography angiography scan (CCTA). The data can be gathered under rest or stress conditions. Estimation of a loss coefficient (K) can be used to eliminate the need for data gathered under stress. The data is used to calculate a transluminal attenuation gradient (TAG). The data may be corrected for imaging artifacts at any stage of the analysis. TAFE is used to determine an estimate of flow velocity. Once velocity is determined, pressure gradient, coronary flow reserve, and/or fractional flow reserve can be determined through a variety of methods. These estimates can be used to estimate functional severity of stenosis.

Abstract: An embodiment in accordance with the present invention provides a method for non-invasively determining the functional severity of coronary artery stenosis. The method includes gathering patient-specific data related to concentration of a contrast agent within a coronary artery of a patient using a coronary computed tomography angiography scan (CCTA). The patient-specific data is used to calculate a patient-specific transluminal attenuation gradient for the coronary artery of the patient. The patient specific transluminal attenuation gradient is used to determine an estimate of a coronary flow velocity, pressure gradient, loss coefficient, coronary flow reserve, and/or fractional flow reserve for the patient. Coronary flow velocity, pressure gradient, loss coefficient, coronary flow reserve, and fractional flow reserve can then be used to estimate the functional severity of coronary artery stenosis.

Abstract: An embodiment in accordance with the present invention provides a method for non-invasively determining the functional severity of coronary artery stenosis. The method includes gathering patient-specific data related to concentration of a contrast agent within a coronary artery of a patient using a coronary computed tomography angiography scan (CCTA). The patient-specific data is used to calculate a patient-specific transarterial attenuation gradient for the coronary artery of the patient. The patient specific transarterial attenuation gradient is compared to previously collected data to determine an estimate of a pressure gradient and/or fractional flow reserve (FFR) for the patient. As more data is collected, the data can be added to the database in order to increase the accuracy of future assessments. The database can also be enhanced by adding data generated by canonical models and mathematical analysis.

Abstract: A shielded component or network for an active medical device (AMD) implantable lead includes (1) an implantable lead having a length extending from a proximal end to a distal end, all external of an AMD housing, (2) a passive component or network disposed somewhere along the length of the implantable lead, the passive component or network including at least one inductive component having a first inductive value, and (3) an electromagnetic shield substantially surrounding the inductive component or the passive network. The first inductive value of the inductive component is adjusted to a account for a shift in its inductance to a second inductive value when shielded.

Abstract: An energy management system that facilitates the transfer of high frequency energy induced on an implanted lead or a leadwire includes an energy dissipating surface associated with the implanted lead or the leadwire, a diversion or diverter circuit associated with the energy dissipating surface, and at least one non-linear circuit element switch for diverting energy in the implanted lead or the leadwire through the diversion circuit to the energy dissipating surface. In alternate configurations, the switch may be disposed between the implanted lead or the leadwire and the diversion circuit, or disposed so that it electrically opens the implanted lead or the leadwire when diverting energy through the diversion circuit to the energy dissipating surface. The non-linear circuit element switch is typically a PIN diode. The diversion circuit may be either a high pass filter or a low pass filter.

Abstract: A shielded component or network for an active medical device (AMD) implantable lead includes (1) an implantable lead having a length extending from a proximal end to a distal end, all external of an AMD housing, (2) a passive component or network disposed somewhere along the length of the implantable lead, the passive component or network including at least one inductive component having a first inductive value, and (3) an electromagnetic shield substantially surrounding the inductive component or the passive network. The first inductive value of the inductive component is adjusted to a account for a shift in its inductance to a second inductive value when shielded.

Abstract: An embodiment in accordance with the present invention provides a method for non-invasively determining the functional severity of coronary artery stenosis. The method includes gathering patient-specific data related to concentration of a contrast agent within a coronary artery of a patient using a coronary computed tomography angiography scan (CCTA). The patient-specific data is used to calculate a patient-specific transluminal attenuation gradient for the coronary artery of the patient. The patient specific transluminal attenuation gradient is used to determine an estimate of a coronary flow velocity, pressure gradient, loss coefficient, coronary flow reserve, and/or fractional flow reserve for the patient. Coronary flow velocity, pressure gradient, loss coefficient, coronary flow reserve, and fractional flow reserve can then be used to estimate the functional severity of coronary artery stenosis.